Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients

Détails

ID Serval
serval:BIB_0804BCB5B759
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients
Périodique
Journal of Nuclear Medicine
Auteur(s)
Buchegger  F., Bonvin  F., Kosinski  M., Schaffland  A. O., Prior  J., Reubi  J. C., Blauenstein  P., Tourwe  D., Garcia Garayoa  E., Bischof Delaloye  A.
ISSN
0161-5505 (Print)
Statut éditorial
Publié
Date de publication
10/2003
Volume
44
Numéro
10
Pages
1649-54
Notes
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Oct
Résumé
The study aim was to assess the safety, biodistribution, tissue kinetics, and tumor uptake of the (99m)Tc-labeled neurotensin (NT) analog NT-XI. METHODS: Four patients presenting ductal pancreatic adenocarcinoma were studied with (99m)Tc-NT-XI. Patients were followed by scintigraphy up to 4 h and by continued blood and urinary sampling until surgery 18-22 h after injection. Surgical tissue samples were analyzed for radioactivity uptake and NT receptor expression. RESULTS: No side effects were observed on injection of (99m)Tc-NT-XI. Blood biologic half-lives alpha and beta were 35 min (range, 17-62 min) and 230 min (range, 107-383 min), respectively. Repeated whole-body scintigraphy performed in 2 patients showed a single exponential decrease of whole-body activity with half-lives of 101 and 232 min. Tracer elimination was mainly renal, with 92% and 98% of activity counted in urine in the first 20 h. Kidney, liver, spleen, and bone marrow activity uptake was observed in all patients. Tumor was not visualized in the first 3 patients but could be localized by tomoscintigraphy in the pancreas head region of patient 4. In vitro tissue analysis showed high expression of NT receptor in the tumor of patient 4, correlated with the highest tumor radioactivity uptake and the highest tumor-to-fat radioactivity ratio. In vitro receptor expression was also positive in a second patient having a tumor characterized by very low cellularity; however, the remaining 2 tumors lacked NT receptor expression. CONCLUSION: Injection of (99m)Tc-NT-XI was well tolerated. The in vivo tumor uptake appeared specific as it was observed in the 1 patient with a pancreatic tumor that expressed high amounts of NT receptor. The results are compatible with preclinical animal results and in favor of further development of radiolabeled NT analogs for diagnosis or therapy of cancer.
Mots-clé
Adenocarcinoma/metabolism/radionuclide imaging Adult Aged Carcinoma, Pancreatic Ductal/*metabolism/*radionuclide imaging Female Half-Life Humans Male Metabolic Clearance Rate Middle Aged Neurotensin/analogs & derivatives/*diagnostic use/*pharmacokinetics Organotechnetium Compounds/*diagnostic use/*pharmacokinetics Pancreatic Neoplasms/*metabolism/*radionuclide imaging Predictive Value of Tests Radiation Dosage Radiometry Radiopharmaceuticals/diagnostic use/pharmacokinetics *Whole-Body Counting
Pubmed
Web of science
Création de la notice
25/01/2008 11:22
Dernière modification de la notice
20/08/2019 12:30
Données d'usage